1. Home
  2. ICHR vs AUPH Comparison

ICHR vs AUPH Comparison

Compare ICHR & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ichor Holdings

ICHR

Ichor Holdings

HOLD

Current Price

$41.76

Market Cap

1.6B

Sector

Technology

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$13.93

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICHR
AUPH
Founded
1999
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.9B
IPO Year
2016
2014

Fundamental Metrics

Financial Performance
Metric
ICHR
AUPH
Price
$41.76
$13.93
Analyst Decision
Strong Buy
Buy
Analyst Count
6
4
Target Price
$45.67
$17.25
AVG Volume (30 Days)
601.8K
1.1M
Earning Date
05-04-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5075.00
EPS
N/A
2.07
Revenue
$947,652,000.00
$283,055,000.00
Revenue This Year
$19.98
$16.53
Revenue Next Year
$15.92
$16.24
P/E Ratio
N/A
$6.90
Revenue Growth
11.61
20.38
52 Week Low
$13.15
$6.83
52 Week High
$55.00
$16.54

Technical Indicators

Market Signals
Indicator
ICHR
AUPH
Relative Strength Index (RSI) 45.01 43.22
Support Level $15.74 $13.52
Resistance Level $55.00 $15.23
Average True Range (ATR) 3.57 0.48
MACD -0.69 -0.01
Stochastic Oscillator 5.87 6.05

Price Performance

Historical Comparison
ICHR
AUPH

About ICHR Ichor Holdings

Ichor Holdings Ltd designs, engineers, and manufactures critical fluid delivery subsystems and components mainly for semiconductor capital equipment, along with solutions for defense/aerospace and medical industries. Its product portfolio includes gas and chemical delivery subsystems that enable precise delivery, monitoring, and control of specialized gases and reactive liquid chemistries used in semiconductor manufacturing processes such as etch, electroplating, and cleaning. The company also provides precision-machined components, weldments, e-beam and laser-welded components, as well as precision vacuum and hydrogen brazing. Geographically, the company operates across the United States, Singapore, Europe, and other regions, with Singapore contributing the majority of revenue.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: